News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Champions Biotechnology, Inc. (CSBR) Partners to Establish Agreements for Preclinical Evaluation of Oncology Drugs


12/18/2008 9:08:49 AM

ARLINGTON, Va.--(BUSINESS WIRE)--Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announces that it has established agreements with Centocor Research & Development, Inc., for the preclinical evaluation of certain therapeutic agents in Centocor’s clinical development pipeline. As part of the agreements, Centocor will utilize Champions Biotechnology’s Biomerk Tumorgrafts™ to evaluate promising antibodies.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES